N
FPRX

Natixis’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Natixis’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-45,887
Closed -$1.73M – 1202
2021
Q1 		$1.73M Buy
+45,887
New +$1.14M 0.01% 731

Natixis's FPRX Position: Q2 2021 in Review

Natixis sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 45,887 shares — an estimated $1.73M sold.

Natixis first reported a position in FPRX in Q1 2021 and held it in 1 quarter. The position peaked at $1.73M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • Natixis reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Natixis sold 45,887 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $1.73M.
  • Natixis first reported a position in Five Prime Therapeutics, Inc. in Q1 2021 and held it in 1 quarter.
  • Natixis's Five Prime Therapeutics, Inc. position peaked at $1.73M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Natixis's 13F filing for Q2 2021, filed 13 Aug 2021.